US Patent 8,815,929: Scope, Claims, Expiration, and Rosacea Patent Landscape

US Patent 8,815,929 covers topical treatment of rosacea-associated erythema with specified alpha-1 adrenergic receptor agonists used as the sole active agent. Its commercial relevance is concentrated in oxymetazoline hydrochloride products, particularly Rhofade. The patent does not claim a composition per se. It claims a method of treating rosacea erythema, with dependent claims directed to dosage form, trigger conditions, concentration, and carrier content. [1]

What does US Patent 8,815,929 claim?

The independent claim requires all of the following elements:

A subject has erythema resulting from rosacea.
A composition is administered topically to the skin.
The composition contains a therapeutically effective amount of an alpha-1 adrenergic receptor agonist.
The alpha-1 agonist is the sole active agent for reducing the erythema.
The active agent is one of eight listed compounds or their hydrochloride salts.

The listed active ingredients are:

Claimed compound	Claimed salt form
Tetrahydrozoline	Tetrahydrozoline hydrochloride
Naphazoline	Naphazoline hydrochloride
Xylometazoline	Xylometazoline hydrochloride
Oxymetazoline	Oxymetazoline hydrochloride

The claim uses “comprising,” so the composition may contain excipients, carriers, preservatives, stabilizers, penetration enhancers, and other non-active formulation ingredients. The “sole active agent” limitation is narrower. A product containing a second pharmacologically active agent could avoid literal infringement of claim 1, depending on the product’s actual composition and the role of the second ingredient.

Does the patent claim oxymetazoline itself?

No. Claim 1 does not claim oxymetazoline as a chemical compound, a composition containing oxymetazoline, or a manufacturing process for oxymetazoline. It claims the topical administration of oxymetazoline for decreasing rosacea-related erythema.

This distinction matters for generic entry. A generic company may be able to manufacture oxymetazoline hydrochloride and sell products for non-rosacea indications without practicing the claimed method. A product labeled for treatment of rosacea erythema would present a substantially greater infringement risk.

What are the dependent claims of US 8,815,929?

Claims 2 through 13 narrow or supplement claim 1.

Claims	Subject matter	Commercial significance
2	Broad list of topical dosage forms	Captures creams, gels, lotions, foams, sprays, emulsions, vesicles and related forms
3	Soaps and cleansing bars	Expands the claim beyond leave-on products
4	Cream	Relevant to Rhofade-type products
5	Gel	Covers gel delivery
6	Lotion	Covers lotion delivery
7	Erythema triggered by foods, hot or alcoholic drinks, temperature, radiation, humidity, wind, surfactants, irritants, cosmetics and related exposures	Targets rosacea flare contexts
8	About 0.1% to about 10% active agent	Broad concentration range
9	About 50% to about 99.999% carrier	Broad carrier limitation
10	About 70% to about 99.99% carrier	Narrower carrier range
11	About 0.05% to about 30% active agent	Broad alternative concentration range
12	About 0.01% to about 20% active agent	Broad alternative concentration range
13	About 0.001% to about 3% active agent	Includes low-dose topical products

Claims 8, 11, 12 and 13 overlap substantially. A 1% oxymetazoline hydrochloride cream, for example, falls within each active-agent range and would also fall within the cream limitation of claim 4.

How broad is the sole-active-agent limitation?

The “sole active agent” language is one of the most important limitations in the patent.

A product is more likely to fall within the claim when:

Oxymetazoline, naphazoline, xylometazoline or tetrahydrozoline is the only pharmacologically active ingredient.
The labeling identifies rosacea erythema reduction as an intended use.
The product is administered topically to the skin.
The product uses one of the claimed dosage forms or concentration ranges.

A product is less likely to satisfy the limitation when:

It contains a second active drug intended to treat rosacea.
The alpha-1 agonist is present only as an inactive formulation component.
The product is used for ocular, nasal or another noncutaneous indication.
The product is marketed solely for cosmetic redness reduction without a rosacea treatment indication, although actual use and induced-infringement theories could still matter.

The claim does not require a particular dosing frequency, treatment duration, skin site, patient age, disease severity, or mechanism beyond the stated alpha-1 agonist activity.

What formulations are protected by US 8,815,929?

The formulation coverage is broad but method-based. The patent reaches topical products in the following categories:

Creams
Gels
Lotions
Ointments
Foams and mousses
Solutions
Emulsions and microemulsions
Milks and serums
Aerosols and sprays
Dispersions
Microcapsules
Vesicles
Microparticles
Soaps and cleansing bars

The patent does not require a specific inactive-ingredient system. A generic formulation could therefore remain within the claim even if it uses a different emulsifier, preservative, solvent, polymer, delivery vehicle, package, or manufacturing process.

A non-infringing formulation strategy would need to address the method claim, not merely alter the excipients. Changing a cream to a gel, or replacing one emulsifier with another, would not avoid infringement if the resulting product still satisfies claim 1.

Does US Patent 8,815,929 cover Rhofade?

Rhofade contains oxymetazoline hydrochloride 1% cream and is approved for the topical treatment of persistent facial erythema associated with rosacea. That product profile maps closely onto the asserted elements of claims 1, 4, 8, 10 and 13. [2]

Rhofade characteristic	Relevance to US 8,815,929
Oxymetazoline hydrochloride	Expressly listed in claim 1
1% concentration	Within all four stated active-agent ranges
Topical administration	Required by claim 1
Cream	Expressly covered by claim 4
Rosacea-associated facial erythema	Required by claim 1
Single pharmacologically active ingredient	Consistent with the sole-active-agent limitation

Rhofade’s FDA-approved active ingredient is oxymetazoline hydrochloride, an alpha-adrenergic agonist. The FDA labeling identifies the product as a topical cream for persistent facial erythema associated with rosacea. [2]

What is the Orange Book status of US 8,815,929?

US Patent 8,815,929 has been associated with the oxymetazoline hydrochloride rosacea product patent estate and is relevant to FDA abbreviated new drug application analysis for a generic version of Rhofade. The Orange Book, however, must be read together with the product-specific patent listing and any later delisting, expiration, or administrative changes. [3]

For a generic applicant, the principal regulatory issue is whether the reference product’s listed patents require:

A Paragraph IV certification alleging invalidity, unenforceability or non-infringement;
A Paragraph III certification accepting delayed approval until patent expiration; or
A Section viii statement carving out a patented method of use.

Because US 8,815,929 is a method-of-treatment patent, a Section viii strategy may be relevant only if the approved labeling can omit the patented rosacea use and still support a viable non-rosacea product. For a generic intended to substitute for Rhofade, that approach is commercially difficult because the patented use is the product’s principal approved indication.

When does US Patent 8,815,929 lose exclusivity?

The patent issued on August 26, 2014. Its enforceable term is determined by the earliest effective nonprovisional filing date or applicable international filing date, together with any patent-term adjustment, terminal disclaimer, or patent-term extension reflected in the USPTO record. [1, 4]

The patent’s nominal statutory framework places expiration in the late 2020s, subject to the official USPTO term calculation. The relevant date for generic planning is not simply the issue date plus 20 years. It is the expiration date shown in the patent’s official term data after accounting for:

The earliest priority and nonprovisional filing dates;
Patent-term adjustment;
Any terminal disclaimer;
Maintenance-fee status;
Patent-term extension, if any.

US 8,815,929 is therefore a late-2020s exclusivity asset rather than a compound patent with a long post-approval life. A generic strategy must also account for later formulation, method, or manufacturing patents that may expire after this patent.

How strong is the patent estate for oxymetazoline rosacea treatment?

The patent is strongest against a product that reproduces the commercial Rhofade profile:

Oxymetazoline hydrochloride;
Approximately 1% strength;
Cream dosage form;
Treatment of rosacea-associated facial erythema;
No second active drug.

Its relative weaknesses are the breadth of the underlying concept and the absence of composition or manufacturing claims in the provided claims.

Strength factors

The estate has several practical enforcement advantages:

Claim 1 directly names oxymetazoline hydrochloride.
The claim tracks the approved use of an oxymetazoline rosacea product.
The dependent claims cover common topical dosage forms.
The concentration claims cover the commercial 1% strength.
A generic label directed to rosacea erythema would provide evidence relevant to induced infringement.

Weakness factors

Potential validity and enforcement issues include:

Prior-art use of topical alpha-adrenergic agonists for vasoconstriction and redness;
Obviousness arguments based on applying known vasoconstrictors to rosacea erythema;
Written-description and enablement questions concerning the eight-compound genus and broad concentration ranges;
Ambiguity over the meaning of “sole active agent” in formulations containing multifunctional excipients;
The method-only character of the claims;
Difficulty proving direct infringement where patients, rather than the manufacturer, administer the product.

The patent’s practical strength therefore depends heavily on the product label, promotional materials, formulation composition, and the scope of any later patents.

How does US 8,815,929 compare with Mirvaso patents?

Mirvaso and Rhofade rely on different active ingredients and different adrenergic pharmacology.

Issue	US 8,815,929 / Rhofade	Mirvaso
Active ingredient	Oxymetazoline hydrochloride	Brimonidine tartrate
Principal receptor characterization	Alpha-1 adrenergic agonist	Alpha-2 adrenergic agonist
Dosage form	Cream	Topical gel
Approved use	Persistent facial erythema associated with rosacea	Persistent facial erythema associated with rosacea
Relevance to US 8,815,929	Directly within claim 1	Generally outside the expressly listed active-ingredient group
Patent risk	Oxymetazoline method and formulation patents	Brimonidine composition, formulation and method patents

The patent should not be treated as a broad patent covering every adrenergic rosacea therapy. Brimonidine is not one of the eight compounds recited in claim 1. A Mirvaso product would require a separate patent analysis. FDA approval records identify the products and their active ingredients. [2, 5]

Which companies are challenging the patent estate?

A Paragraph IV certification is not the same as a court finding of invalidity or non-infringement. Generic applicants may challenge listed patents through an ANDA filing, but the commercial outcome depends on litigation, settlement, FDA approval timing, and any 30-month stay under the Hatch-Waxman framework. [6]

The critical diligence points are:

Identify every ANDA applicant with an oxymetazoline hydrochloride rosacea product.
Determine whether the applicant filed Paragraph IV certifications against US 8,815,929.
Check whether the patent owner filed suit within 45 days.
Review any settlement for launch dates, licenses, authorized-generic rights, or covenants not to sue.
Separate this patent from later patents covering particle size, vehicle composition, stability, packaging, or manufacturing.

A patent number alone does not establish that a particular generic company has challenged the patent. Litigation status must be confirmed through PACER, the FDA Orange Book, USPTO records, and company disclosures. [3, 7]

What generic launch risks exist for oxymetazoline cream?

A generic launch can occur through several routes:

Launch route	Risk profile
Full rosacea label with Paragraph IV challenge	Highest litigation exposure; potentially earliest commercial substitution
Section viii carve-out	Limited utility if rosacea is the commercially necessary indication
Launch after patent expiration	Lower litigation risk but later market entry
Non-rosacea oxymetazoline product	May avoid the claimed use, but labeling and actual-use evidence remain relevant
Design-around with a second active agent	May implicate the sole-active-agent limitation but creates regulatory and clinical complications

The most credible challenge would likely focus on invalidity and non-infringement rather than a simple excipient design-around. A 1% oxymetazoline hydrochloride cream labeled for rosacea would closely track the claim language.

What licensing and commercial issues affect the patent landscape?

The commercial chain may involve separate entities for:

Patent ownership;
FDA sponsorship of the reference NDA;
Product commercialization;
Manufacturing;
Generic development;
Authorized-generic distribution.

A license or assignment does not change the claim scope. It changes enforcement authority, royalty economics, and settlement leverage. Transaction diligence should compare USPTO assignment records with FDA NDA ownership and corporate disclosures. The relevant records include the patent assignment database, Orange Book listing, SEC filings, and product-label history. [2, 3, 4]

Revenue exposure is concentrated in products that depend on oxymetazoline rosacea treatment rather than in the broader oxymetazoline market. Nasal, ophthalmic and other oxymetazoline products generally do not practice the claimed method unless they are used topically on skin to treat rosacea erythema.

What geographic coverage does US 8,815,929 provide?

The patent provides rights only in the United States. Equivalent rights require separate national or regional patents, and the claim scope may differ materially by jurisdiction.

For international freedom-to-operate work, the relevant family should be reviewed across:

United States;
European Patent Office jurisdictions;
Canada;
Japan;
South Korea;
Australia;
Brazil;
China;
Other markets where topical oxymetazoline rosacea products are commercialized.

Foreign claims may have different active-ingredient lists, priority dates, prosecution amendments, term dates and validity outcomes. A US non-infringement position does not establish freedom to operate abroad.

Key Takeaways

US 8,815,929 is a method-of-treatment patent for topical reduction of rosacea erythema.
Claim 1 expressly covers oxymetazoline and oxymetazoline hydrochloride.
The “sole active agent” limitation is central to both infringement and design-around analysis.
A 1% oxymetazoline hydrochloride cream for rosacea closely matches the claim set.
The patent does not claim oxymetazoline as a molecule, a composition per se, or a manufacturing process.
Mirvaso’s brimonidine-based product is not within the expressly listed active-ingredient group.
Generic substitution for Rhofade creates greater risk than non-rosacea oxymetazoline products.
Patent expiration should be determined from official USPTO term data, not the issue date alone.
Later formulation and manufacturing patents may create exclusivity after this patent expires.
Paragraph IV, Section viii, litigation and settlement analysis must be conducted across the full Orange Book-listed estate.

FAQs

Can a generic use a different cream base to avoid US 8,815,929?

No. A different vehicle, emulsifier or preservative would not avoid infringement if the product still uses a listed alpha-1 agonist topically to treat rosacea erythema as the sole active agent.

Is 1% oxymetazoline hydrochloride specifically protected?

It is within every active-agent concentration range recited in claims 8, 11, 12 and 13, assuming the other limitations are satisfied.

Does the patent cover nasal oxymetazoline products?

Not based on the provided claims. The claims require topical administration to the skin for erythema resulting from rosacea.

Could a combination product avoid the patent?

A combination product may challenge the “sole active agent” limitation, but that position would depend on whether the additional ingredient is legally and technically an active agent, how the product is labeled, and how it is marketed and used.

Does expiration of US 8,815,929 eliminate all Rhofade generic-entry barriers?

No. Later patents covering formulations, delivery systems, stability, manufacturing or other product attributes may remain enforceable after this patent expires.

References

U.S. Patent No. 8,815,929. (2014). Methods of treating rosacea. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (n.d.). Rhofade (oxymetazoline hydrochloride) cream, 1% prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
United States Patent and Trademark Office. (n.d.). Patent Center and patent assignment database. USPTO.
U.S. Food and Drug Administration. (n.d.). Mirvaso (brimonidine tartrate) topical gel prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug application patent certifications. FDA.
Administrative Office of the U.S. Courts. (n.d.). PACER: Public Access to Court Electronic Records. U.S. Courts.

Details for Patent: 8,815,929

Summary for Patent: 8,815,929